Protective immunity of single and multi-antigen DNA vaccines against schistosomiasis

Nascimento, Eduardo J. M.; Leao, Ihid Carneiro; Pereira, Valéria Rêgo Alves; Gomes, Yara M.; Chikhlikar, Priya R.; August, Thomas J.; Marques, Ernesto T. A.; Lucena‐Silva, Norma

doi:10.1590/s0074-02762002000900021

Cited by 23 publications

(19 citation statements)

References 28 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, using an integral membrane protein (Sm23) and several different DNA immunization regimens (e.g., microseeding, gene gun delivery, and intramuscular injections) and coadministration of plasmid DNA encoding both IL-4 and IL-12, protection ranging from 18 to 44% has been recorded (15,16). Furthermore, a combination of three plasmids encoding two tegumental antigens (ECL and Sm14) and a muscular antigen (IrV-5) yielded protection levels ranging from 41 to 65% (37). We believe that exploitation of the antigens described above is hindered, first by a lack of consensus as to the appropriate immune response to be elicited, as discussed recently (58), although a mouse concomitant immunity model seems appropriate given the Th1 responses associated with healthy individuals with endemic infection.…”

Section: Discussionmentioning

confidence: 99%

Induction of Protective Immunity againstSchistosoma mansonivia DNA Priming and Boosting with the Large Subunit of Calpain (Sm-p80): Adjuvant Effects of Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-4

et al. 2003

View full text Add to dashboard Cite

Considerable morbidity and mortality result from schistosomiasis, an affliction affecting an estimated 200 million people. Although schistosomicidal drugs and other control measures (including public hygiene and snail control) exist, the advent of an efficacious vaccine remains the most potentially powerful means for controlling this disease. We have targeted a vaccine candidate (large subunit of calpain, Sm-p80) because of its consistent immunogenicity, protective potential, and integral role in surface membrane biogenesis of schistosomes. Since surface membrane renewal appears to be one of the major phenomena employed by schistosomes to evade the host's immune system; an immune response directed against Sm-p80 should render the parasite susceptible to immune clearance from the host by both providing a focus of attack and by potentially impairing the membrane repair process. In the present study, we have employed DNA immunization protocols using Sm-p80 with plasmids encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4). Sm-p80 by itself provided 39% protection (P ‫؍‬ <0.0001) against challenge infection in C57BL/6 mice. This protection was increased to 44% (P ‫؍‬ <0.0001) when the plasmid encoding GM-CSF was coadministered with Sm-p80 DNA. Coinjection of plasmid DNA encoding IL-4 with Sm-p80 DNA yielded a protection level of 42% (P ‫؍‬ <0.0001). Statistically, the protection conferred by including GM-CSF, but not IL-4, was significantly greater than that when only Sm-p80 was used. Sm-p80 DNA by itself elicited strong responses that include IgG2A and IgG2B antibody isotypes. The introduction of GM-CSF DNA with Sm-p80 DNA led to distinct increases in total IgG and IgG1 titers, whereas the coadministration of IL-4 DNA with Sm-p80 DNA resulted in a slight elevation of IgG1 and IgG3 titers and in some reduction of IgG2A and IgG2B titers. Our data again indicate that Sm-p80 can be an excellent candidate for a schistosomiasis vaccine.

show abstract

Section: Discussionmentioning

confidence: 99%

Induction of Protective Immunity againstSchistosoma mansonivia DNA Priming and Boosting with the Large Subunit of Calpain (Sm-p80): Adjuvant Effects of Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-4

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Furthermore, using an integral membrane protein (Sm23) and several different DNA immunization regimens (e.g., microseeding, gene gun delivery, and intramuscular injections) and coadministration of plasmid DNA encoding both the murine IL-4 and IL-12 genes, protection ranging from 18% to 44% has been recorded (Da'dara et al 2001;Da'dara et al 2002). Furthermore, a combination of three plasmids encoding two tegumental antigens (200-kDa glycosylphosphatidylinositolanchored surface protein commonly referred to as ECL and Sm14) and a muscular antigen (IrV-5) yielded protection levels ranging from 41% to 65% (Nascimento et al 2002). Using Sm23 in a DNA-prime/protein-boost vaccination regimen, an enhanced Th2 immune response was achieved but the protection levels were greatly reduced from the 36-44% routinely achieved with Sm23 DNA priming alone.…”

Section: Vaccine Candidatesmentioning

confidence: 99%

Experimental vaccines in animal models for schistosomiasis

et al. 2008

View full text Add to dashboard Cite

Considerable morbidity and mortality results from the affliction of an estimated 200 million people worldwide by several species of schistosomes; 779 million are exposed to the disease in 74 different countries. Even though anti-parasitic drugs and other control measures, including public hygiene and snail control are available, the advent of an effective vaccine still remains the most potentially powerful means for the control of this disease. The putative vaccine could be administered to small children prior to the time when their contact with infected water is maximal, so as to prevent severe infection in the subsequent years. This review attempts to summarize the status of schistosome vaccine development with special emphasis on functionally important vaccine candidates. The importance of utilizing both murine and nonhuman primate models as a prerequisite for clinical trials is discussed.

show abstract

“…(2) Studies have been carried out in the Oswaldo Cruz Institute in order to develop vaccines. (7) The case reported shows the need to consider schistosomiasis in the differential diagnosis of lung tumors seen in imaging studies, since Brazil is among the countries with the highest prevalence of the disease. multiplication of similar lesions leads to pulmonary hypertension.…”

Section: Discussionmentioning

confidence: 93%

Forma pseudoneoplásica de esquistossomose pulmonar crônica sem hipertensão pulmonar

et al. 2009

View full text Add to dashboard Cite

A esquistossomose é uma doença que, no Brasil, é causada pelo Schistosoma mansoni e transmitida através da água por moluscos do gênero Biomphalaria. Essa espécie ocorre na África, nas Antilhas e na América do Sul. O parasita, ao atingir a fase adulta de seu ciclo biológico no sistema vascular do homem, alcança as veias mesentéricas. Cada fêmea põe cerca de 400 ovos por dia, e estes, a partir da submucosa, chegam à luz intestinal. Há relatos de casos a respeito de ovos de S. mansoni nos pulmões de pacientes sem evidência de fibrose hepática. Relatamos um caso dessa forma atípica de apresentação da doença. O paciente apresentava dor torácica não-ventilatóriodependente, perda ponderal significativa e tosse seca. A TC de tórax mostrou uma tumoração irregular no lobo inferior esquerdo, mas somente a biópsia pulmonar evidenciou ovos de S. mansoni degenerados. O paciente não apresentava sinais clínicos de hipertensão pulmonar ou portal, as quais tampouco foram diagnosticadas através de exames.

show abstract

Protective immunity of single and multi-antigen DNA vaccines against schistosomiasis

Abstract: We evaluated the usefulness of the combination of three plasmids encoding tegumental (pECL and pSM14)

Cited by 23 publications

References 28 publications

Induction of Protective Immunity againstSchistosoma mansonivia DNA Priming and Boosting with the Large Subunit of Calpain (Sm-p80): Adjuvant Effects of Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-4

Induction of Protective Immunity againstSchistosoma mansonivia DNA Priming and Boosting with the Large Subunit of Calpain (Sm-p80): Adjuvant Effects of Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-4

Experimental vaccines in animal models for schistosomiasis

Forma pseudoneoplásica de esquistossomose pulmonar crônica sem hipertensão pulmonar

Contact Info

Product

Resources

About